Table 2.
Effect of decorporation treatment with diethylenetriaminepentaacetic acid after inhalation of a poorly soluble plutonium-239 compound or injection into a wound of a soluble compound (1 μCi) depending on the treatment initiation time
| Treatment Start Time | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| None | 1 h | 2 h | 6 h | 12 h | 1 Day | 2 Days | 10 Days | 30 Days | 90 Days | 180 Days | |
| Committed effective dose (mSv) | |||||||||||
| Inhalation | 260 | 4.7 | 4.7 | 5.0 | 5.8 | 8.3 | 15 | 70 | 150 | 214 | 224 |
| Wound | 823 | 9.7 | 10 | 14 | 24 | 57 | 143 | 501 | 581 | 663 | 701 |
| Therapeutic efficacy | |||||||||||
| Inhalation | 0 | 0.98 | 0.98 | 0.98 | 0.98 | 0.97 | 0.94 | 0.73 | 0.42 | 0.18 | 0.14 |
| Wound | 0 | 0.99 | 0.99 | 0.98 | 0.97 | 0.93 | 0.83 | 0.39 | 0.29 | 0.19 | 0.15 |
A treatment duration of 180 days is assumed. The calculations of the committed effective dose for 50 years are based on the wound model of Konzen and Brey30 and the ICRP systemic model for plutonium.22,23 For each treatment start time, the dose reduction factor was calculated by dividing the committed effective dose absorbed under treatment by the dose without treatment and the efficacy was estimated by subtracting the dose reduction factor from one.
ICRP, International Commission on Radiological Protection.